Furegrelate sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 575718

CAS#: 87463-91-0

Description: Furegrelate sodium is a thromboxane synthase inhibitor that attenuates the renal vasoconstriction of angiotensin II, presumably by enhancing the formation of vasodilator prostaglandins.

Chemical Structure

img
Furegrelate sodium
CAS# 87463-91-0
Instruction

Theoretical Analysis

MedKoo Cat#: 575718
Name: Furegrelate sodium
CAS#: 87463-91-0
Chemical Formula: C15H12NNaO4
Exact Mass: 293.07
Molecular Weight: 293.250
Elemental Analysis: C, 61.44; H, 4.12; N, 4.78; Na, 7.84; O, 21.82

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Furegrelate sodium; U-63,557A

IUPAC/Chemical Name: Sodium 5-(3-pyridylmethyl)-2-benzofurancarboxylate monohydrate

InChi Key: UVXKTLQOOXTOML-UHFFFAOYSA-M

InChi Code: InChI=1S/C15H11NO3.Na.H2O/c17-15(18)14-8-12-7-10(3-4-13(12)19-14)6-11-2-1-5-16-9-11;;/h1-5,7-9H,6H2,(H,17,18);;1H2/q;+1;/p-1

SMILES Code: O.[Na+].[O-]C(=O)c1oc2ccc(Cc3cccnc3)cc2c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 293.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hirenallur-S DK, Detweiler ND, Haworth ST, Leming JT, Gordon JB, Rusch NJ. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. doi: 10.4103/2045-8932.97605. PubMed PMID: 22837860; PubMed Central PMCID: PMC3401873.

2: Pestel S, Nath A, Jungermann K, Schieferdecker HL. Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate. Biochem Pharmacol. 2003 Aug 15;66(4):643-52. PubMed PMID: 12906929.

3: Kaushal RD, Wilson TW. Effect of furegrelate on renal plasma flow after angiotensin II infusion. Can J Physiol Pharmacol. 1990 Apr;68(4):500-4. PubMed PMID: 2328452.

4: Martorell A, Sagredo A, Aras-López R, Balfagón G, Ferrer M. Ovariectomy increases the formation of prostanoids and modulates their role in acetylcholine-induced relaxation and nitric oxide release in the rat aorta. Cardiovasc Res. 2009 Nov 1;84(2):300-8. doi: 10.1093/cvr/cvp214. Epub 2009 Jun 30. PubMed PMID: 19567483.